Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Tracleer

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Background: Obstructive sleep apnea (OSA) is strongly correlated with an increased risk of systemic hypertension. However, the… Expand
2013
2013
Bosentan (Tracleer) is an endothelin receptor antagonist prescribed for the treatment of pulmonary arterial hypertension (PAH… Expand
2013
2013
AIM To evaluate the efficiency and safety of long-term (12-month) treatment with the endothelin receptor antagonist bosentan… Expand
2012
2012
To the Editor: Liver toxicity is the most common reason for drug withdrawals ([1][1]). Drug-related hepatotoxicity is rare… Expand
  • figure 1
Highly Cited
2007
Highly Cited
2007
The elimination process of the endothelin receptor antagonist bosentan (Tracleer) in humans is entirely dependent on metabolism… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 3
2007
2007
  • C. Schmidt
  • Nature Biotechnology
  • 2007
  • Corpus ID: 919216
When Merck KGaA purchased Geneva-based Serono in September, Actelion became Switzerland's largest biotech. 
2006
2006
  • J. Ransom
  • Nature Biotechnology
  • 2006
  • Corpus ID: 28513596
The best-performing stock from 2005 was a prime example of how biotech stocks are not as capricious as they may seem. 
2006
2006
S A N D I E G O — A second randomized clinical trial has confirmed that treatment with bosentan can help prevent the formation of… Expand
2003
2003
  • Drug and therapeutics bulletin
  • 2003
  • Corpus ID: 38335064
Pulmonary arterial hypertension is an uncommon but disabling and often fatal condition, in which there is a sustained rise in… Expand
Review
2002
Review
2002